25 Aug 2010
25 Aug 2010
Presentation: CogState launches Axon Sports, LLC in the United States
CogState Ltd (ASX: CGS) today announced the official launch of its joint venture with Quixote Investment: Axon Sports, LLC, in the United States. Axon Sports will market and sell a cutting-edge Computerised Cognitive Assessment Tool (CCAT) to protect the athletic brain. CogState's technology is at the backbone of the CCAT, and Axon Sports has an exclusive license to use and sell the technology, initially in the sports market in North America only.CogState Chairman, Martyn Myer along with CEO, Brad O'Connor joined Rudy Chapa, Patricia Eiting and Polly James from Axon Sports, to host a presentation via teleconference to discuss the launch today.
During the call they explained the business opportunity that currently exists in North America in the area of concussion management, introduced Axon Sports and the key people behind it, and explained why CogState believes Axon Sports will be successful and what that will mean for CogState and its shareholders.That presentation is available by following this link:
http://www.brr.com.au/event/67827/mr-brad-oconnor-ceo
25 Aug 2010
CogState FY2010 Annual Report
CogState has released its Annual Report in respect of the year ended 30 June 2010.
A fully copy of the Annual Report can be viewed by clicking here.
24 Aug 2010
Media Alert: CogState to launch Axon Sports tomorrow
CogState will launch Axon Sports on Wednesday, August 25 at 11:30 AM (Australian E.S.T).
For more details, and information on attending, see the attached media alert.
31 Mar 2010
Natural History of Concussion in Sport: Markers of Severity and Implications for Management
Background: Evidence-based clinical data are required for safe return to play after concussion in sport.
Purpose: The objective of this study was to describe the natural history of concussion in sport and identify clinical features associated
with more severe concussive injury, using return-to-sport decisions as a surrogate measure of injury severity.
Methods: Male elite senior, elite junior, and community-based Australian Rules football players had preseason baseline cognitive testing (Digit Symbol Substitution Test, Trail-Making Test–Part B, and CogSport computerized test battery). Players were recruited into the study after a concussive injury sustained while playing football. Concussed players were tested serially until all clinical features of their injury had resolved.
Results: Of 1015 players, 88 concussions were observed in 78 players. Concussion-associated symptoms lasted an average of 48.6 hours (95% confidence interval, 39.5-57.7 hours) with delayed return to sport correlated with _4 symptoms, headache lasting _60 hours, or self-reported ‘‘fatigue/fogginess.’’ Cognitive deficits using the Digit Symbol Substitution Test and Trail-Making Test–part B recovered concomitantly with symptoms, but computerized test results recovered 2 to 3 days later and remained impaired in 35% of concussed players after symptom resolution.
Conclusion: Delayed return to sport was associated with initially greater symptom load, prolonged headache, or subjective concentration deficits. Cognitive testing recovery varied, taking 2 to 3 days longer for computerized tests, suggesting greater sensitivity to impairment. Therefore, symptom assessment alone may be predictive of but may underestimate time to complete recovery, which may be better estimated with computerized cognitive testing.
*This article can be found here , or in our Publications section.
*To receive a copy of this publication, please contact us: http://www.cogstate.com/go/contact.
11 Mar 2010
Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies.
Introduction: Computerized cognitive testing has the potential to be an effective way to assess and monitor cognition in large neuroepidemiological studies. CogState is a game-like computerized test with demonstrated validity and reliability that has shown sensitivity to decline in older individuals over time. This study aimed to evaluate the serial usability of the test specifically within an older community cohort.
Methods: The test battery was administered to healthy volunteers aged 50 and above at 3 month intervals over 12 months in a community setting. Test usability was examined in terms of acceptability, efficiency and stability.
Results: Of 301 subjects (age: 61.9 ± 7.2), 87% completed the study. In addition, 85% completed the first test within the allowed time and passed integrity criteria with performance improving and stabilising at subsequent visits. The computerized battery required on average 15 minutes for administration allowing 263 patients to be assessed on 5 occasions by two assessors. All tasks showed stability and high test-retest reliability with serial administration.
Conclusions: This computerized test was shown to have good acceptability, efficiency and stability for the repeated assessment of cognitive function in older people. Together with its demonstrated sensitivity to cognitive impairment and cognitive change, these data suggest that it would be a useful tool for application in neuroepidemiological studies.
*To see this publication, please visit our Publications section.
*To receive a copy of this publication, please contact us: http://www.cogstate.com/go/contact.
11 Mar 2010
Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies.
Introduction: Computerized cognitive testing has the potential to be an effective way to assess and monitor cognition in large neuroepidemiological studies. CogState is a game-like computerized test with demonstrated validity and reliability that has shown sensitivity to decline in older individuals over time. This study aimed to evaluate the serial usability of the test specifically within an older community cohort.
Methods: The test battery was administered to healthy volunteers aged 50 and above at 3 month intervals over 12 months in a community setting. Test usability was examined in terms of acceptability, efficiency and stability.
Results: Of 301 subjects (age: 61.9 ± 7.2), 87% completed the study. In addition, 85% completed the first test within the allowed time and passed integrity criteria with performance improving and stabilising at subsequent visits. The computerized battery required on average 15 minutes for administration allowing 263 patients to be assessed on 5 occasions by two assessors. All tasks showed stability and high test-retest reliability with serial administration.
Conclusions: This computerized test was shown to have good acceptability, efficiency and stability for the repeated assessment of cognitive function in older people. Together with its demonstrated sensitivity to cognitive impairment and cognitive change, these data suggest that it would be a useful tool for application in neuroepidemiological studies.
*To see this publication, please visit our Publications section.
*To receive a copy of this publication, please contact us: http://www.cogstate.com/go/contact.
25 Aug 2009
CogState FY2009 Annual Report
CogState has released its Annual Report in respect of the year ended 30 June 2009, which shows that CogState recorded a Net profit After Tax of $1.4 million ($0.022 per share) on total revenue of $8.6 million. Revenue was up 120% on the previous financial year. A full copy of the 2009 Annual Report can be viewed here:
http://www.cogstate.com/go/corporate/investors/investor-reports
25 Aug 2009
CogState FY2009 Annual Report
CogState has released its Annual Report in respect of the year ended 30 June 2009, which shows that CogState recorded a Net profit After Tax of $1.4 million ($0.022 per share) on total revenue of $8.6 million. Revenue was up 120% on the previous financial year. A full copy of the 2009 Annual Report can be viewed here:
http://www.cogstate.com/go/corporate/investors/investor-reports
19 May 2009
Detection of MCI in the clinic: evaluation of the sensitivity and specificity of a computerised test battery
Introduction: the sensitive detection of mild cognitive impairment (MCI) in older adults is an important problem that requires objective assessment. We evaluated whether the computerised cognitive test battery, CogState, was as sensitive to MCI as two well-validated ‘paper-and-pencil’ tests, the Hopkins Verbal Learning Test (HVLT) and the Mini-Mental Status Examination (MMSE).
Methods: these tests were administered with a subjective memory questionnaire and an ‘Activities of Daily Living’ scale to 21 individuals with MCI and 98 cognitively healthy controls matched for sex, education and IQ levels. The sensitivity and specificity of the tests and their discrimination between groups were determined.
Results: the HVLT had a maximum discrimination between controls and MCI cases of 90%, compared with 86% for CogState and 65% for the MMSE. Only CogState showed correlations with subjective memory complaints (SMC) and activities of daily living for the whole cohort when controlled for age, sex and years of education. Logistic regression analyses showed that diagnosis (control:MCI) was predicted by HVLT and a CogState ratio score. Age was a significant predictor of HVLT performance, while age and SMC predicted CogState performance. The computerised test battery was well tolerated by older adults, but presentation speed was a limiting factor for some participants.
Conclusions: overall, we conclude that the HVLT has better sensitivity for the detection of MCI in older adults than the CogState, but that CogState may enable the identification of cognitive deficits above and beyond impairments in memory.
*To receive a copy of this publication, please contact us: http://www.cogstate.com/go/contact
19 May 2009
Detection of MCI in the clinic: evaluation of the sensitivity and specificity of a computerised test battery
Introduction: the sensitive detection of mild cognitive impairment (MCI) in older adults is an important problem that requires objective assessment. We evaluated whether the computerised cognitive test battery, CogState, was as sensitive to MCI as two well-validated ‘paper-and-pencil’ tests, the Hopkins Verbal Learning Test (HVLT) and the Mini-Mental Status Examination (MMSE).
Methods: these tests were administered with a subjective memory questionnaire and an ‘Activities of Daily Living’ scale to 21 individuals with MCI and 98 cognitively healthy controls matched for sex, education and IQ levels. The sensitivity and specificity of the tests and their discrimination between groups were determined.
Results: the HVLT had a maximum discrimination between controls and MCI cases of 90%, compared with 86% for CogState and 65% for the MMSE. Only CogState showed correlations with subjective memory complaints (SMC) and activities of daily living for the whole cohort when controlled for age, sex and years of education. Logistic regression analyses showed that diagnosis (control:MCI) was predicted by HVLT and a CogState ratio score. Age was a significant predictor of HVLT performance, while age and SMC predicted CogState performance. The computerised test battery was well tolerated by older adults, but presentation speed was a limiting factor for some participants.
Conclusions: overall, we conclude that the HVLT has better sensitivity for the detection of MCI in older adults than the CogState, but that CogState may enable the identification of cognitive deficits above and beyond impairments in memory.
*To receive a copy of this publication, please contact us: http://www.cogstate.com/go/contact
28 Apr 2009
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging aimed to recruit 1000 individuals aged over 60 to assist with prospective research into Alzheimer’s disease (AD). This paper describes the recruitment of the cohort and gives information about the study methodology, baseline demography, diagnoses, medical comorbidities, medication use, and cognitive function of the participants.
Methods: Volunteers underwent a screening interview, had comprehensive cognitive testing, gave 80 ml of blood, and completed health and lifestyle questionnaires. One quarter of the sample also underwent amyloid PET brain imaging with Pittsburgh compound B (PiB PET) and MRI brain imaging, and a subgroup of 10% had ActiGraph activity monitoring and body composition scanning.
Results: A total of 1166 volunteers were recruited, 54 of whom were excluded from further study due to comorbid disorders which could affect cognition or because of withdrawal of consent. Participants with AD (211) had neuropsychological profiles which were consistent with AD, and were more impaired than participants with mild cognitive impairment (133) or healthy controls (768), who performed within expected norms for age on neuropsychological testing. PiB PET scans were performed on 287 participants, 100 had DEXA scans and 91 participated in ActiGraph monitoring.
Conclusion: The participants comprising the AIBL cohort represent a group of highly motivated and wellcharacterized individuals who represent a unique resource for the study of AD. They will be reassessed at 18-month intervals in order to determine the predictive utility of various biomarkers, cognitive parameters and lifestyle factors as indicators of AD, and as predictors of future cognitive decline.
*To receive a copy of this publication, please contact us: http://www.cogstate.com/go/contact
25 Mar 2009
Validity of the CogState Brief Battery
This study examined the validity of the four standard psychological paradigms that have been operationally defined within the CogState brief computerized cognitive assessment battery. Construct validity was determined in a large group of healthy adults. CogState measures of processing speed, attention, working memory, and learning showed strong correlations with conventional neuropsychological measures ofthese same constructs (r’s ¼ .49 to .83). Criterion validity was determined by examining patterns of performance on the CogState tasks in groups of individuals with mild head injury, schizophrenia, and AIDS dementia complex. Each of these groups was impaired on theCogState performance measures (Cohen’s d’s ¼ 2.60 to 21.80) and the magnitude and nature of this impairment was qualitatively and quantitatively similar in each group. Taken together, the results suggest that the cognitive paradigms operationally defined in the CogState brief battery have acceptable construct and criterion validity in a neuropsychological context.
*To receive a copy of this publication, please contact us: http://www.cogstate.com/go/contact
27 Feb 2009
Methodological Improvements in Quantifying Cognitive Change in Clinical Trials
Abstract: Objectives: Change in cognitive function in response to a pharmacologic challenge can be observed
with greater sensitivity by employing cognitive tests with optimal psychometric properties and a statistical
approach that more accurately accounts for individual variability in performance. To demonstrate this approach
we examined the cognitive effects of a single acute dose administration of an acetylcholinesterase inhibitor,
donepezil, in healthy older adults and in older adults with mild Alzheimer’s disease (AD). Design: Placebocontrolled
crossover study with three separate testing days: baseline, placebo, and donepezil, with assessments at
baseline, and 1-, 2-, 3-, 6-, and 8-hrs post-dosing on each day. Setting: Early phase I clinical trial. Participants:
15 healthy older adults; 14 older adults with mild Alzheimer’s disease. Intervention: Single acute dose of 5mg
donepezil. Measurements: Performance on the Groton Maze Learning Test (GMLT), a computerized
neuropsychological measure of spatial working memory and error monitoring. Results: A single acute dose of
donepezil improved GMLT performance in healthy older adults (effect size: 0.83 at 6 hrs post-dosing) and older
adults with mild AD (effect size: 0.58 at 3 hrs post-dosing). Conclusion: The GMLT detected cognitive
improvement following a single, acute dose administration of donepezil in healthy older adults and older adults
with mild AD. The choice of cognitive tests designed for repeated administration, as well as an analytic
approach that emphasizes individual-level change in cognitive function, provides a sensitive approach to
detecting central nervous system drug penetration and activity of cognitive-enhancing agents.
*To receive a copy of this publication, please contact us: http://www.cogstate.com/go/contact
26 Feb 2009
Taylor Collison report
To view please click link below
http://library.cogstate.com/public/indepreps/Taylor%20Collison%20Analyst%20Report%20Feb%202009.pdf
25 Feb 2009
ASX Announcement: Half year maiden profit result and full year guidance
ASX Announcement
Melbourne, 25 February 2009
Half year maiden profit result and full year guidance
Highlights:
Half year NPAT of $1.29 million on revenue of $3.92 million
Revenue increase of 135%
Contracts already in place will generate $3.4 million of revenue in future periods
Forecast revenue for the second half of the financial year in the range of $3.0 - $3.5 million, of which $2 million is already under contract
Full year NPAT guidance of $1.50 - $1.75 million, based on the above revenue forecast
Half Year Result CogState Ltd (ASX: CGS) today released its Appendix 4D and Half Year Financial Report for the period ended 31 December 2008. CogState recorded its maiden profit result during the half year, posting a net profit after tax (NPAT) of $1.29 million. The profit result was driven by a strong increase in revenues, up 135% to $3.92 million (2007: $1.67 million). CogState, which prices its sales contracts in US dollars, also benefited from the falling Australian dollar, recording a net gain on foreign exchange of $0.65 million for the half year. During the half year to 31 December 2008, CogState signed sales contracts with a combined value in excess of A$4.2 million, a 75% increase in the value of contracts signed for the half year to 31 December 2007 (2007: A$2.4 million). Industry Conditions CogState’s customers are predominantly large pharmaceutical companies, such as Pfizer, AstraZeneca, GlaxoSmithKline, Merck and Dainippon Sumitomo, among others. In light of the continuing impact of the macro economic conditions, some large pharmaceutical companies, including some of CogState’s customers, are reviewing their operations and planned research and development expenditure. On the back of this, CogState expects that it will see a reduction in the number of smaller, exploratory, phase 1 clinical trials that are conducted by pharmaceutical companies in the coming months.
In respect of planned and budgeted phase 2 and 3 clinical trials, particularly in lead indications such as Alzheimer’s disease and Schizophrenia, CogState anticipates some reduction in research and development expenditure. However, because of their importance to the future revenue base of pharmaceutical companies, many of these planned phase 2 and 3 clinical trials must proceed. Even in the current environment, CogState has continued to see new sales opportunities for the use of its technology and services, particularly in larger, later stage (phase 2 and 3) clinical trials. Expansion Plans Following the decision not to renew the agreement with United Biosource Corporation, CogState will add operational resources to support the conduct of existing and new clinical trials. A small number of additional staff will be added to the current headcount, with a mix of staff located in the United States and the United Kingdom. It is expected that the new staff will be added progressively over the next six months. The cost of new operational resources will be offset by the additional revenue that will retained by CogState, following the end of the UBC agreement and associated revenue sharing between the two companies. In addition, CogState will focus on technological automation, designed to deliver operational efficiencies and, over time, reduce the number of resources required to manage a given number of clinical trials. Revenue and Profit Guidance for the Financial Year CogState currently has contracts in place that will generate $3.4 million of revenue in future periods. Of that future revenue, approximately $2 million of revenue from existing contracts is expected to be recognised during the half year to 30 June 2009. CogState expects to record revenue in the range of $3.0 - $3.5 million for the half year ending 30 June 2009. This forecast is based on the $2 million revenue currently under contract in addition to new contracts that are expected to be executed during the half year. CogState is forecasting a NPAT in the range of $1.50 - $1.75 million for the year ending 30 June 2009, based on forecast revenue and budgeted costs.
About CogState
CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials. Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, AstraZeneca, GlaxoSmithKline, Merck, Abbott Laboratories, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group), Lundbeck and Organon USA. CogState is currently expanding its existing activities in the US and European clinical trial markets. For additional information:
Brad O’Connor
Chief Executive Officer
CogState Ltd.
03 9664 1300
Mob: 0411 888 347
boconnor@cogstate.com
14 Jan 2009
A comparison of the CogState Schizophrenia Battery and the Measurement
This study examined the criterion and construct validity of a brief computerized cognitive test battery (CogState
Schizophrenia Battery) compared to a conventional cognitive test battery recommended by the Measurement and
Treatment Research to Improve Cognition in Schizophrenia (MATRICS) consensus. The CogState and
MATRICS batteries yielded comparable effect sizes in comparing patients with schizophrenia to healthy controls
(Cohen’s ds = –1.50 for both batteries). Moderate to large correlations were observed between CogState andMATRICS measures of processing speed, attention/vigilance, working memory, verbal and visual learning,
reasoning/problem solving, and social cognition (rs =.56–.79). CogState and MATRICS composite scores alsocorrelated strongly with scores on the University of California at San Diego (UCSD) Performance-Based Skills
Assessment (UPSA; rs = .76 and .79, respectively) in patients with schizophrenia. Results of this study suggestthat the CogState Schizophrenia Battery provides valid measurement of the cognitive domains nominated by the
MATRICS consensus group as being important to consider in the context of pharmacological treatments for
cognitive impairment in schizophrenia.
*To receive a copy of this publication, please contact us: http://www.cogstate.com/go/contact
23 Oct 2008
AGM Presentation
To view please click link below
29 Jul 2008
CogState Forms Strategic Partnership with UBC
COGSTATE LTD. AND UNITED BIOSOURCE CORPORATION FORM STRATEGIC PARTNERSHIP TO SUPPORT COGNITIVE ASSESSMENT IN CLINICAL RESEARCH
Driven by customer demand, market leaders align resources to build comprehensive service offering to standardize the administration, measurement and global implementation of cognitive testing in clinical trials
BETHESDA, MD - July 28, 2008. United BioSource Corporation (UBC) and CogState Ltd. are pleased to announce that they have entered into a strategic partnership to facilitate the use of cognitive testing within clinical trials for pharmaceutical and life sciences companies . Customers will be able to leverage CogState's scientific and software capabilities with UBC's global operations to support full scale clinical development programs.
Cognitive impairment is a defining feature of many psychiatric and neurological diseases including Alzheimer's disease, schizophrenia, Parkinson's disease, ADHD, depression and stroke. Consequently, improving cognition has become an important outcome for new treatment strategies in these conditions, increasing the need for sensitive measures, assays and analyses that can be used to guide decisions about cognition. Furthermore there is also a need for processes and systems to cost-effectively manage the use of cognitive assessments in multi-national clinical development programs.
Within this context, UBC and CogState have teamed up to advance the field of cognitive assessment in clinical trials through the provision of an integrated cognitive testing solution for use in multi-national Phase I through IV clinical trials. The comprehensive cognitive service solution provided by the partnership will provide new opportunities for sponsor companies seeking the global, operational depth of UBC coupled with the power of CogState's industry-leading cognitive testing expertise.
CogState has earned a solid reputation in scientific research for its standard and customized test batteries as well as reliable computerized testing systems and methods of analysis of cognitive data. It has proven itself as a leader in cognition testing and offers sponsor companies the most innovative and appropriate cognitive assessment strategies, including computerized testing, and traditional paper and pencil batteries such as the Neuropsychological Test Battery (NTB) developed by Dr John Harrison, Principal Scientist for CogState. CogState clinical trials systems also include real-time data reporting programs which provide sites with new opportunities for both immediate data read-out and data monitoring and quality review.
In response to the increasing focus on cognitive assessment within clinical trials, CogState sought out an established, global pharmaceutical services company with a proven methodology for ensuring data quality in clinical trials. "UBC's customized, hands-on approach to rater training, assessment and ongoing rater surveillance is a perfect fit with CogState's portfolio of evidence-based cognitive testing capabilities," said Brad O'Connor, CEO of CogState.
UBC's leading Ratings Services group is focused on standardizing the administration and scoring of clinically subjective outcome measures used as pivotal endpoints in clinical trials. Its data collection, data monitoring and training services are designed to reduce data variance and maximize inter-site reliability across countries. UBC has trained, certified and monitored more than 20,000 raters, testers and investigators in more than 60 countries encompassing over 400 protocols.
Catherine Spear, Senior Vice-President of UBC's Ratings Services group states, "UBC and CogState have demonstrated an unsurpassed commitment to ensuring measurement precision and data quality within clinical research. Our combined offering will provide customers with a comprehensive solution for cognitive testing that addresses both the operational and scientific challenges associated with clinical research. Sponsor companies will be better equipped to select the most appropriate cognitive tests; train, certify and support raters and testers administering the batteries; centrally monitor test data; and interpret test results. Ultimately, companies will be able to improve the timeliness, effectiveness and precision of their trials that include cognitive testing."
Enthusiasm for this new partnership is felt by the scientific leaders at both organizations. "We are excited about offering comprehensive global training and operational services from UBC to our customers and we look forward to supporting UBC customers with our innovative cognitive testing tools. The UBC global project delivery capabilities are unmatched in the pharmaceutical services industry. The partnership will allow CogState to more efficiently deliver training and site support, thereby further assuring the quality of data," said CogState Principal Scientist Paul Maruff, PhD.
David Miller, MD, a UBC Practice Leader with a specialty in dementia trials and other neurological disorders stated, "CogState's validated, evidence-based platform for cognitive testing together with UBC's proven training, certification and data monitoring methodology will provide sponsor companies with unparalleled support."
"The growing importance of cognition as a pivotal endpoint in clinical development has increased the need for scalable, evidence-based cognitive testing solutions," stated Professor Peter Snyder, a leading international researcher in Alzheimer's disease, Professor of Clinical Neuroscience at Brown University and Scientific Consultant to CogState. "By seamlessly integrating science, technology and client service, the combination of UBC and CogState will provide pharmaceutical and life sciences companies with the most complete and integrated cognitive testing approach", added Professor Snyder.
CogState and UBC will remain independent legal entities and will maintain their respective names. Likewise, the executive management of will also remain the same for both companies. UBC and CogState will immediately begin to work together to support sponsor companies with the assessment of cognition in clinical trials.
CogState Ltd. is headquartered in Melbourne, Australia and also has an office in the United States located in New Haven, CT. For more information, visit www.cogstate.com or call +61-3-9664-1300.
UBC is headquartered in Bethesda, Maryland, with offices in the United States, Canada, Eastern and Western Europe and South America. For more information, visit www.unitedbiosource.com or call +1 866-458-1096.
###
17 Apr 2008
A study using CogState sheds new light on ‘Chemofog’.
Women who have undergone chemotherapy often report problems with their memory and concentration levels. However, two new studies suggest that the stress of the diagnosis, rather than the chemotherapy itself, may be the cause of these problems.
Video featuring Dr. David Darby, Chief Medical Officer of CogState Ltd. discussing his findings at the 60th Annual AAN Meeting:
Click here for the full article from Science Daily22 Nov 2007
ASX Release: CogState Signs Agreement for Phase IIb Schizophrenia Trial
Key points:
- CogState tests will be used to objectively measure cognition as an endpoint in a Phase IIb Schizophrenia trial run by an international pharmaceutical company
- Study to be run in multiple European and South American sites, in multiple languages
- CogState was selected after a competitive tender process
- The contract will generate gross revenue in excess of A$0.7m for CogState over the course of the trial (approx. 2 years)
CogState Ltd (ASX:CGS) announced today that it has signed an agreement with an international pharmaceutical company for the use of CogState's cognitive testing technology, and associated services, in a Phase IIb trial to be conducted at a large number of sites throughout Europe and South America. The trial will investigate the benefits of a new therapy for schizophrenia against a leading antipsychotic drug.
One of the key criteria for selection of cognitive service provider was the ability to manage a trial across a large number of sites, countries and languages. CogState's advanced, real time data management systems were viewed as capable of providing the high level of study site support and data monitoring & management required for an international, multicentre trial.
Mr Brad O'Connor, Chief Executive Officer of CogState, said: "It is pleasing to see our customers acknowledging our cognitive test solution and data management systems as the best in the industry for collection, tracking and management of cognitive data in their trials. CogState's real time data management systems mean that we are well placed to manage the data collected in multi-centre studies, conducted anywhere in the world."
Mr O'Connor added: "This contract is the tenth contract since 1 July 2007. Including the contract announced today, the collective value of contracts signed since 1 July 2007 is A$2 million."
About CogState
CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.
Since sales into the clinical trials market began in 2004, CogState has secured agreements with organizations including Pfizer, Merck, Lundbeck, GlaxoSmithKline, AstraZeneca, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group), and Organon USA. CogState is currently expanding its existing activities in the US and European clinical trial markets.
For additional information:
Brad O'Connor
Chief Executive Officer
CogState Ltd.
Ph: 03 9664 1300 or 0411 888 347
boconnor@cogstate.com
Rebecca Piercy
Buchan Consulting
Ph: 02 9237 2800
Mob: 0422 916 422
rpiercy@bcg.com.au
21 Aug 2007
ASX Release: CogState Signs Agreement for Phase IV Trial with Pfizer
Key points:- Phase IV trial conducted by Pfizer throughout Europe will use CogState technology and services
- Cognition, as measured by change in CogState score, is the primary endpoint for the trial
CogState Ltd (ASX:CGS) announced today that it has signed an agreement with Pfizer for the use of CogState's cognitive testing technology, and associated services, in a Phase IV trial to be conducted in more than 20 sites throughout Europe.
The trial will investigate the benefits of growth hormone replacement therapy in patients suffering from severe growth hormone deficiency after traumatic brain injury, and will focus on the potential effects on cognitive function.
The primary endpoint of the trial will be the change from baseline in CogState scores after 36 weeks.
Mr Brad O'Connor, Chief Executive Officer of CogState, said: "It is pleasing to see our customers relying on our scientific expertise and technology solutions to answer primary study questions. We are particularly well suited for use in this trial because of our experience and scientific expertise with respect to brain injury. Further, with CogState's real time data management systems, we are well placed to manage the data collected in multi-centre studies, conducted anywhere in the world."
Mr O'Connor added: "Coming on the back of recent contracts with Merck, GalxoSmithKline and AstraZeneca, this contract is particularly encouraging and indicates an increasing level of demand for CogState's technology and associated services."
About CogState
CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.
Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, Merck, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group), Organon USA and GlaxoSmithKline. CogState is currently expanding its existing activities in the US clinical trial markets.
For additional information:
Brad O'Connor
Chief Executive Officer
CogState Ltd.
Ph: 03 9664 1300 or 0411 888 347
boconnor@cogstate.com
Rebecca Piercy
Buchan Consulting
Ph: 02 9237 2800
Mob: 0422 916 422
rpiercy@bcg.com.au
18 Jul 2007
ASX Release: CogState signs first agreement with AstraZeneca
Key points:- CogState technology to be used for the first time by AstraZeneca in a clinical trial
- AstraZeneca is a global healthcare company
CogState Ltd (ASX:CGS) announced today that it has signed its first agreement with AstraZeneca for the use of CogState's cognitive testing technology, and associated services.
The agreement with AstraZeneca is consistent with CogState's business strategy to target leading pharmaceutical companies that have substantial central nervous system portfolios of drugs in development, which will require cognitive testing as part of the clinical trial. CogState currently has on-going contracts with companies such as Pfizer, Abbott Laboratories, GlaxoSmithKline, Merck & Co Inc. and Lundbeck A/S.
Mr Brad O'Connor, Chief Executive Officer of CogState, said: "We are working with an increasing number of the leading global pharmaceutical companies that specialise in drug development for central nervous system indications. I am really pleased to see our hard work pay off as we add this new and important customer to our existing base."
About CogState
CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.
Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, Merck, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group), Organon USA and GlaxoSmithKline. CogState is currently expanding its existing activities in the US clinical trial markets.
For additional information:
Brad O'Connor
Chief Executive Officer
CogState Ltd.
Ph: 03 9664 1300 or 0411 888 347
boconnor@cogstate.com
Rebecca Piercy
Buchan Consulting
Ph: 02 9237 2800
Mob: 0422 916 422
rpiercy@bcg.com.au
13 Jul 2007
ASX Release: CogState signs second agreement with GlaxoSmithKline
CogState Ltd (ASX:CGS) announced today that it is has signed a second contract with global research-driven pharmaceutical company, GlaxoSmithKline, for the use of CogState's cognitive testing technology and associated services in a clinical trial due to start this year.
Mr Brad O'Connor, Chief Executive Officer of CogState, said: "CogState's continued revenue growth is dependent upon our ability to work with our pharmaceutical company customers on an on-going basis. We are extremely pleased to be announcing this contract with GlaxoSmithKline, especially on the back of the recent announcement regarding a second contract with Merck."
About CogState
CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.
Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, Merck, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group), Organon USA and GlaxoSmithKline. CogState is currently expanding its existing activities in the US clinical trial markets.
For additional information:
Brad O'Connor
Chief Executive Officer
CogState Ltd.
Ph: 03 9664 1300 or 0411 888 347
boconnor@cogstate.com
Rebecca Piercy
Buchan Consulting
Ph: 02 9237 2800
Mob: 0422 916 422
rpiercy@bcg.com.au
09 Jul 2007
ASX Release: CogState signs second agreement with Merck
CogState Ltd (ASX:CGS) announced today that it is has signed a second contract with global research-driven pharmaceutical company, Merck & Co., Inc. for the use of CogState's cognitive testing technology and associated services in a clinical trial due to start this year.
Mr. Brad O'Connor, chief executive officer of CogState, said, "As one of the largest pharmaceutical companies in the world, with an extensive CNS portfolio, Merck is a valued customer of CogState. This second contract is evidence of the strengthening relationship between the companies."
About CogState
CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.
Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, Merck, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group), Organon USA and GlaxoSmithKline. CogState is currently expanding its existing activities in the U.S. clinical trial markets.
For additional information:
Brad O'Connor
Chief Executive Officer CogState Ltd.
Ph: 03 9664 1300 or 0411 888 347
boconnor@cogstate.com
13 Jun 2007
CogState scientists give 3 poster presentations at 47th annual NCDEU Meeting
Three CogState scientists have been invited to make poster presentations at the annual New Clinical Drug Evaluation Unit (NCDEU) annual meeting held in Boca Raton, Florida, USA during June 11-14.
The NCDEU Meeting is a scientific conference that brings together academic researchers from multiple disciplines involved in clinical trials, investigators with the pharmaceutical industry, and representatives from NIMH/NIH and the Food and Drug Administration (FDA) to address psychopharmacology, clinical trials methodology, and the broader areas of interventions and services research.
The meeting will address other timely issues relevant to clinical research in psychiatry, such as the training and development of clinical researchers, recruitment of research participants, and the ethics of clinical studies.
Now in its 47th year, the NCDEU meeting is considered to be a highlight by researchers in the field of mental health.
View Our Posters:
- The Acute Effects of Adjuvant Chemotherapy on Cognitive Function in Women with Breast Cancer
- Stability of cognitive performance in chronic schizophrenia over brief and intermediate re-test intervals: Implications for studies of treatment efficacy
- Statistical Methods for Classifying change in Cognitive Function in Individuals following Scopolamine: The use of Effect Sizes
Please note: For copyright reasons, a password is needed to view these posters. Please contact us for the password.
01 Feb 2007
ASX Release: CogState signs its first agreement with Abbott
Key points:- CogState technology to be used for the first time by Abbott in a clinical trial
- CogState's contracted future revenue exceeds A$2.1m
- Abbott is a global healthcare company
CogState Ltd (ASX:CGS) announced today that it has signed its first agreement with Abbott for the use of CogState's cognitive testing technology and associated services, in a Phase I clinical trial.
Abbott is a global, broad-based healthcare company devoted to discovering new medicines, new technologies and new ways to manage health. Abbott has a substantial central nervous system portfolio of drugs in development.
CogState already has sales contracts with leading companies in the field of central nervous system drug development, including companies such as Pfizer, GlaxoSmithKline, Merck and Alza Corporation (part of Johnson & Johnson), whereby CogState's technology is used in their clinical trials.
Mr Brad O'Connor, Chief Executive Officer of CogState, said: "CogState continues to be focussed on growing our customer base of pharmaceutical companies. This agreement represents another success for the company and is an excellent example of the hard work we have been putting into expanding sales in the US market."
Following today's announced agreement with Abbott, the total value of CogState's contracted future revenue exceeds A$2.1m. Contracted future revenues are revenue amounts to be recognised in coming periods, from signed agreements currently in place.
About CogState
CogState Ltd (ASX: CGS) specialises in the development and commercialisation of rapid, computerised tests of cognition (brain function). The tests are sold to pharmaceutical, biotechnology, nutraceutical and functional food companies to quantify the effect of drugs or other interventions on human subjects participating in clinical trials.
Since sales into the clinical trials market began in 2004, CogState has secured agreements with organisations including Pfizer, Merck, Centres for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group), Organon USA and GlaxoSmithKline. CogState is currently expanding its existing activities in the US clinical trial markets.
For additional information:
Brad O'Connor
Chief Executive Officer
CogState Ltd.
Ph: 03 9664 1300 or 0411 888 347
boconnor@cogstate.com
Rebecca Piercy
Buchan Consulting
Ph: 02 9237 2800
Mob: 0422 916 422
rpiercy@bcg.com.au
30 Jan 2007
CogState Health to be used in a community screening project
Project Title: Community screening for very early dementia using medically supervised detection of cognitive decline.
Number of participants: Approximately 300.
A new research project will focus on a subject that is of concern to many people - the perception that their memory seems to be getting worse as they age.
While there is an increasing number of people with dementia, most people (especially younger people) who worry about their memory don't have dementia.
This research project will test the application of an inexpensive, widespread, validated population-based computerised cognitive screening technique, called CogHealth. The project offers an opportunity to members of the community aged 50 years of age or over to establish a cognitive baseline, and to then measure any changes every 3 months, over a one year period. Anyone who is detected to have significant memory problems will be offered more detailed assessment or told how to access it.
The study will be conducted by Associate Professor David Darby of the Centre for Neuroscience at the University of Melbourne and Chief Medical Officer of CogState Ltd, and supported by Associate Professor Michael Woodward, Director, Aged and Residential Care Services, Austin Health and Alzheimer's Australia Vic.
The study uses the scientifically validated computerized test of memory and thinking called CogHealth which was developed in Melbourne and uses game-like playing card tasks independent of language to measure a person's speed and accuracy at baseline and then every 3 months over a year. The CogHealth test has been shown to detect such early changes in research volunteers where an individual's baseline is compared several times over 12 months, but is now to be field-tested in a community setting to determine whether a screening program is feasible and acceptable to persons with concerns about their memory and to their medical practitioners. If the study shows that CogHealth is a useful and practical screening method for detecting persons who will need more detailed medical evaluation, then this program will pave the way for wider scale population-based screening programs in time for imminent specific therapies for Alzheimer's Disease. Early detection coupled with early treatment has the potential to prevent the development of significant memory and thinking deterioration.
The study is now recruiting interested volunteers from the community to participate.
Persons are eligible if they are:
(i) at least 50 years of age;
(ii) able to travel to either Hawthorn or Heidelberg testing sites;
(iii) have no existing memory or thinking impairment;
(iv) can use a computer;
(v) have a current GP;
(vi) are willing to participate with at least 6 visits over a 12 month period, each visit being approximately 15-30 minutes.
Interested persons are invited to phone the ComScreen Study Registration Line 1300 MY MIND (1300 69 64 63).
To find out more about Alzheimer's Australia, Click Here.
16 Jan 2007
CogState issued US patent
CogState today announced that it has been issued a patent from the Unites States Patent & Trade Mark Office (US patent no. 7,163,513) for the key technology platform used in its computer-based tests of brain function. The patent term adjustment is 229 days.
As announced in July 2006, this patent broadly protects CogState's psychological testing method which randomises the nature and timing of the visual stimuli presented to a subject as well as the apparatus used in such tests. The patent also protects the company's unique approach to cross cultural and non language specific based testing which uses acultural visual stimuli.
This is the first US patent for CogState, which also holds a patent in Australia (patent number 2001275604), issued in April 2005.
08 Dec 2006
CogState ranks no. 12 in the 2006 Deloitte Technology Fast50.
The Deloitte Technology Fast50 is a program that recognises and profiles fast growing technology companies in Australia. Nominated companies are measured on revenue growth over a three year period, and must have had minimum revenue of $100k in the first year and $1m in the third year.CogState has been eligible for the program for the last 2 years. In 2005, we were ranked 21st in Australia and this year we ranked 12th Nationally and 2nd in Victoria, after achieving 981% revenue growth over three years.
This result also places CogState near the top of the fastest growing companies in the wider Asia Pacific Region - the fastest growing region in the world.
CogState would like to take this opportunity to thank everyone who made this result possible and also to congratulate the overall winner in the 2006 Deloitte Technology Fast50 - Unwired Group.
To read the full report, please click here.
